Another mpox vaccine, LC16, made by Japan's KM Biologics, can already be given to children, according to the Japanese regulator, although it requires a special kind of needle.

After approving Bavarian Nordic’s mpox vaccine in September for use in adults, the World Health Organisation has given the vaccine the green light for use in adolescents aged 12 to 17 years. It ...

WHO authorizes Bavarian Nordic vaccine for mpox, offering hope for countries battling the disease. Vaccine can be used off-label for children and immunocompromised individuals.

The first mpox vaccine approved by the WHO is MVA-BN, made by Bavarian Nordic A/S. It was approved for emergency use and can be used "off-label" in infants, children and adolescents as well as in ...

GENEVA — The World Health Organization on Tuesday approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use, the second one to get the agency's seal of approval. The ...

The World Health Organization on Tuesday approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use, the second one to get the agency's seal of approval.

In its announcement Friday, the WHO said that it was authorizing the vaccine for adults but that it could be used at the discretion of health care providers for children and adolescents younger ...

Available data shows that a single-dose MVA-BN vaccine given before exposure has an estimated 76% effectiveness in protecting people against mpox, with the 2-dose schedule achieving an estimated ...

Bavarian Nordic receives WHO prequalification for IMVANEX as the first vaccine against mpox, accelerating access in African countries.

Key takeaways: Jynneos was safe and generated an antibody response in adolescents that was similar to that seen in adults. The new data could help expand the number of people eligible for the vaccine.

The U.N. health agency approved the two-dose mpox vaccine for people aged 18 and above. WHO said that while it was not recommending the vaccine for those under 18, the shot may be used in infants ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...